Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MCAG Mountain Crest Acquisition Corp. V
10.1870.0000.00%
Trading Session
01/31 09:30 ET
High
0.000
Open
0.000
Turnover
0.00
Low
0.000
Pre Close
10.187
Volume
0.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma
SINGAPORE and BETHESDA, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced
AUM Biosciences Receives FDA ODD for AUM302
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma
SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. ("AUM"), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced
AUM Biosciences Receives Human Research Ethics Committee Approval To Commence Phase II Clinical Trial Of AUM001 For Treatment Of Metastatic Colorectal Cancer In Australia
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage candidate and a broader pipeline designed to deploy multi-faceted inhibition strategies to reverse
Insider Sell: Mountain Crest Acquisition Corp. V
04:12 PM EDT, 10/21/2022 (MT Newswires) -- Suying Liu, 10% Owner, Director, CEO and CFO, on October 19, 2022, sold 100,000 shares in Mountain Crest Acquisition Corp. V (MCAGU) for $1,000,000. Followin
Mountain Crest Acquisition to Merge With AUM Biosciences
06:33 AM EDT, 10/20/2022 (MT Newswires) -- Mountain Crest Acquisition Corp. V entered into a definitive business combination agreement with AUM Biosciences Pte. Ltd. The company said Thursday that t
Cancer Drugmaker Aum Biosciences to Go Public via SPAC Mountain Crest
AUM Biosciences to Become a Public Company via Merger With Mountain Crest Acquisition Corp. V
AUM Biosciences Pte. Ltd. ("AUM"), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer resistance, and
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) Short Interest Update
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG – Get Rating) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 70
Short Interest in Mountain Crest Acquisition Corp. V (NASDAQ:MCAG) Drops By 20.6%
Mountain Crest Acquisition Corp. V (NASDAQ:MCAG – Get Rating) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 2,700 shares, a
Company Overview
More
Mountain Crest Acquisition Corp. V is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on April 8, 2021 and is headquartered in New York, NY.
CEO： Dr. Suying Liu, PhD
Market： NASDAQ
Listing Date： 11/12/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet